Pro- and anti-inflammatory cytokines are significantly decreased at acute time points following IR. by Jordan A. Gunning (18143970)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

DHA decreased cell viability in HepG3 cells. by Arlet Hernandez (12289155)

Depletion of putative SDH subunits leads to decreased SDH activity and oxygen consumption. by Mariana F. Silva (10219520)

Mean and standard error of the mean for force capability according to anchor point level change. by Jihun Kim (10091)

Subjects:

Homozygous deletion of <i>ERG251</i> leads to the decreased ergosterol accumulation in the absence of FLC and decreased production of toxic dienol in the presence of FLC. by Xin Zhou (54275)

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Task variability/correlations decrease independently of mean task activity removal step in fMRI data. by Takuya Ito (57473)

HRV parameters at different time points. by Shiying Liu (1569478)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Divergence from transmitted/founder (TF) virus increases during ART-naïve infection and decreases on treatment. by Kelsie Brooks (8928044)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: